Dexamethasone in Cryptococcal Meningitis

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000776
Collaborator
(none)
36
14
2.6

Study Details

Study Description

Brief Summary

To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension.

In AIDS patients with cryptococcal meningitis, a correlation has been found between early death and elevated intracranial pressure. Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis, it may be of benefit in AIDS patients with cryptococcal meningitis.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

In AIDS patients with cryptococcal meningitis, a correlation has been found between early death and elevated intracranial pressure. Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis, it may be of benefit in AIDS patients with cryptococcal meningitis.

Patients are randomized to receive dexamethasone or placebo every 6 hours for 72 hours (days 1 through 3). Additionally, standard antifungal therapy with amphotericin B and flucytosine is given for 2 weeks, followed by fluconazole for 8 weeks. Lumbar punctures will be performed daily on days 1 through 3, on days 7 and 14, and at week 10.

Study Design

Study Type:
Interventional
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Dexamethasone in Cryptococcal Meningitis
Actual Study Completion Date :
Sep 1, 1996

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Concurrent Medication:
    Allowed:
    • Aerosolized pentamidine or systemic chemoprophylaxis for PCP.

    • Preventive therapy for steroid-associated ulcers and any other therapies required to manage steroid toxicity (e.g., insulin).

    Patients must have:
    • Documented initial episode or relapse of acute cryptococcal meningitis. (NOTE: Patients must be untreated for this episode except for administration of a test dose of 1 g or less amphotericin B.)

    • Acute cryptococcal meningitis with cerebrospinal fluid opening pressure >= 250 mm H2O prior to receipt of antifungal therapy for this episode.

    • Documented HIV infection OR a diagnosis of AIDS based on a documented AIDS-defining opportunistic infection.

    • Ability to begin therapy within 8 hours after the pre-entry lumbar puncture.

    • Consent of parent or guardian if less than 18 years of age.

    NOTE:
    • Comatose patients eligible provided informed consent can be provided by guardian or next of kin.

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following symptoms or conditions are excluded:
    • Concurrent CNS disease such as another infection or neoplasm that would interfere with assessment of response.

    • Prison incarceration.

    Concurrent Medication:
    Excluded:
    • Acetazolamide, mannitol, urea preparations, and other corticosteroids during the first 72 hours of the study.

    • Treatment or prophylaxis with other systemic antifungal agents at any time.

    • Antiretroviral therapy during the first 72 hours of the study.

    Prior Medication:
    Excluded within 7 days prior to study entry:
    • Corticosteroids, mannitol, urea preparations, acetazolamide, or more than 24 hours of phenytoin.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Univ of Alabama at Birmingham Birmingham Alabama United States 35294
    2 Georgetown Univ Med Ctr Washington District of Columbia United States 20007
    3 Univ of Miami School of Medicine Miami Florida United States 331361013
    4 Northwestern Univ Med School Chicago Illinois United States 60611
    5 Cook County Hosp Chicago Illinois United States 60612
    6 Bronx Municipal Hosp Ctr/Jacobi Med Ctr Bronx New York United States 10461
    7 Jack Weiler Hosp / Bronx Municipal Hosp Bronx New York United States 10465
    8 Bronx Veterans Administration / Mount Sinai Hosp Bronx New York United States 10468
    9 SUNY / Health Sciences Ctr at Brooklyn Brooklyn New York United States 112032098
    10 SUNY / Erie County Med Ctr at Buffalo Buffalo New York United States 14215
    11 Beth Israel Med Ctr New York New York United States 10003
    12 Mount Sinai Med Ctr New York New York United States 10029
    13 Ohio State Univ Hosp Clinic Columbus Ohio United States 432101228
    14 Univ of Puerto Rico San Juan Puerto Rico 009365067

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)

    Investigators

    • Study Chair: J Jacobson,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT00000776
    Other Study ID Numbers:
    • ACTG 202
    • 11178
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Oct 28, 2021
    Last Verified:
    Oct 1, 2021

    Study Results

    No Results Posted as of Oct 28, 2021